Figure 1.
Increasing Vγ2Vδ2 T cell numbers or changing the route of transfer does not improve immunity against human PC-3 prostate tumors in immunodeficient NSG mice. (a) Schema of treatment protocol used to evaluate the anti-tumor efficacy of Vγ2Vδ2 T cells. Human PC-3 prostate cancer cells were injected s.c. into immunodeficient NSG mice on day 0. On day 13, pamidronate (50 μg/kg) was given i.v. On day 14, cryopreserved purified Vγ2Vδ2 T cells expanded using pulse zoledronate stimulation were inoculated i.v. or i.p. Treatments were repeated weekly until week 6. Longitudinal and transverse diameters of the tumors were measured weekly. (b) (left panel) Increasing the number of cryopreserved Vγ2Vδ2 T cells does not improve anti-tumor immunity. Mean PC-3 tumor volume ± SD is shown for 3–8 mice per group treated with either pamidronate alone (closed circles), or pamidronate with 1 × 106 (open circles), 31 × 106 (open triangles), or 62 × 106 (open inverted triangles) purified Vγ2Vδ2 T cells. (right panel) Tumor volumes at week 6 for individual mice. Bars represent mean values. (c) (left panel) Changing the route of adoptively transferred Vγ2Vδ2 T cells does not improve anti-tumor immunity. Mean PC-3 tumor volume ± SD is shown for 5–6 mice per group treated with either pamidronate alone (closed circles), or pamidronate with 1 × 106 purified Vγ2Vδ2 T cells given i.v. (open circles) or i.p. (open triangles). (right panel) Tumor volumes at week 7 for individual mice. Bars represent mean values. *p < .05, **p < .01, ***p < .001 compared with the tumor volume in mice treated with pamidronate alone using the Mann-Whitney U test